Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

17.69
-0.0700-0.39%
Post-market: 17.860.1700+0.96%18:15 EDT
Volume:2.13M
Turnover:37.65M
Market Cap:2.22B
PE:-9.85
High:18.09
Open:17.85
Low:17.46
Close:17.76
Loading ...

David O. Watson, General Counsel, Reports Disposal of Common Shares of Apellis Pharmaceuticals Inc

Reuters
·
18 Jun

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Biogen (BIIB) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
12 Jun

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Steris (STE) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
09 Jun

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Apellis Pharmaceuticals (APLS) and Bio-Rad Laboratories (BIO)

TIPRANKS
·
09 Jun

Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study

MT Newswires Live
·
06 Jun

Apellis, Sobi present data from open-label period of Phase 3 VALIANT study

TIPRANKS
·
06 Jun

Apellis Pharmaceuticals and Sobi Announce Ongoing FDA and EMA Review of EMPAVELI® for C3G and IC-MPGN Treatment

Reuters
·
06 Jun

Apellis and Sobi Announce Empaveli® (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3g and Primary Ic-Mpgn

THOMSON REUTERS
·
06 Jun

Apellis Pharmaceuticals Inc - No New Safety Signals Observed in Study

THOMSON REUTERS
·
06 Jun

Apellis Pharmaceuticals Inc - Empaveli Shows Favorable Safety and Tolerability

THOMSON REUTERS
·
06 Jun

Apellis Pharmaceuticals Inc - Robust Proteinuria Reduction and Stable Kidney Function Maintained in Study

THOMSON REUTERS
·
06 Jun

Apellis Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
05 Jun

Apellis Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
02 Jun

Apellis Pharmaceuticals Files Initial Beneficial Ownership Statement for Kelley Boucher, Chief People Officer

Reuters
·
29 May

Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Apellis Pharmaceuticals (APLS)

TIPRANKS
·
23 May

Apellis Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
23 May

Apellis Pharmaceuticals Inc : Citigroup Cuts Target Price to $41 From $49

THOMSON REUTERS
·
22 May

Apellis price target lowered to $41 from $49 at Citi

TIPRANKS
·
22 May

Stock Track | Apellis Pharmaceuticals Plummets 5% as Mizuho Slashes Price Target

Stock Track
·
15 May

Mizuho Securities Adjusts Apellis Pharmaceuticals Price Target to $20 From $30, Maintains Neutral Rating

MT Newswires Live
·
13 May